Gadolinium-Based Nanoparticles and Radiation Therapy for Multiple Brain Melanoma Metastases: Proof of Concept before Phase I Trial

Citations Over TimeTop 1% of 2016 papers

Abstract

Nanoparticles containing high-Z elements are known to boost the efficacy of radiation therapy. Gadolinium (Gd) is particularly attractive because this element is also a positive contrast agent for MRI, which allows for the simultaneous use of imaging to guide the irradiation and to delineate the tumor. In this study, we used the Gd-based nanoparticles, AGuIX®. After intravenous injection into animals bearing B16F10 tumors, some nanoparticles remained inside the tumor cells for more than 24 hours, indicating that a single administration of nanoparticles might be sufficient for several irradiations. Combining AGuIX® with radiation therapy increases tumor cell death, and improves the life spans of animals bearing multiple brain melanoma metastases. These results provide preclinical proof-of-concept for a phase I clinical trial.

Related Papers

• → Gadolinium Retention in the Rat Brain: Assessment of the Amounts of Insoluble Gadolinium-containing Species and Intact Gadolinium Complexes after Repeated Administration of Gadolinium-based Contrast Agents(2017)110 cited
• → Gadolinium-based contrast agents: From gadolinium complexes to colloidal systems(2019)46 cited
• → Elemental Imaging of Long-term Gadolinium Retention in Rodent Femur(2022)7 cited
• → Gadolinium(III) 3,5,5-trimethylhexanoate complexes for creation of stable Gd-loaded liquid organic scintillators(2016)9 cited
• → Experimental study on intracranial gadolinium deposition in rats after linear conversion to macrocyclic gadolinium contrast agent(2023)